TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

Five years of continuous Briumvi kept MS relapse rates and disability progression low, according to analyses from a trial's ...

TG Therapeutics stock rose Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

TG Therapeutics, Inc. (NASDAQ:TGTX) stock is trading higher on Wednesday after the company announced it updated its data ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...

US CDMO BioCentriq has appointed Syed Husain as its new CEO. Husain, who brings over 20 years of experience in CDMO ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Boston Scientific (BSX – Research Report) with bullish ...

As of 03:52PM EDT. Market open. S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on ...